ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©×ÔÑÐMEK1/2ÒÖÖƼÁFCN-159Ƭ»ñµÚ¶þÏîÍ»ÆÆÐÔÁÆ·¨È϶¨
(ͼΪCDE¹ÙÍø¹«Ê¾ÐÅÏ¢)
IÐÍÉñ¾ÏËάÁö²¡£¡£¡£¡£¡£¡£¡£¨ neurofbromatosis type 1£¬£¬£¬£¬£¬NF1£©ÊÇÒ»ÖÖ³£È¾É«ÌåÏÔÐÔÒÅ´«²¡£¡£¡£¡£¡£¡£¡£¬£¬£¬£¬£¬ÆäRAS-Ë¿ÁÑԻÂÑ°×¼¤Ã¸£¨RAS-MAPK£©ÐźÅͨ·ÔöÇ¿£¬£¬£¬£¬£¬µ¼ÖÂÖ×ÁöÑØÉñ¾Éú³¤¡£¡£¡£¡£¡£¡£¡£20£¥-50£¥µÄIÐÍÉñ¾ÏËάÁö²¡ÌåÏÖΪ´Ô×´Éñ¾ÏËάÁö£¨Plexiform neurofibromas£¬£¬£¬£¬£¬PN£©£¬£¬£¬£¬£¬²¢¿ÉÄܵ¼ÖÂÌÛÍ´¡¢¹¦Ð§Ë𺦡¢»ÙÈݺͶñÐÔת»¯µÈ²¢·¢Ö¢[1]¡£¡£¡£¡£¡£¡£¡£ÏÖÔÚ£¬£¬£¬£¬£¬ÊÖÊõÊÇÕâÀàÖ×ÁöµÄÖ÷ÒªÖÎÁÆÊֶΣ¬£¬£¬£¬£¬µ«ÁÆЧÊÜÏÞ[2]£¬£¬£¬£¬£¬¶ø¹ØÓÚ³ÉÈË»¼ÕßÀ´Ëµ£¬£¬£¬£¬£¬ÏÖÔÚ»¹Ã»ÓÐÒ©Îï»ñÅú¡£¡£¡£¡£¡£¡£¡£
2023Äê6ÔÂÃÀ¹úÁÙ´²Ö×Áöѧ»áÄê»á£¨ASCO£©ÉÏ£¬£¬£¬£¬£¬ÒÔposterµÄÐÎʽչʾÁËFCN-159ÔÚ³ÉÈËNF1µÄ1/2ÆÚÑо¿Ð§¹û»ã×ÜÆÊÎö£¬£¬£¬£¬£¬Ñо¿Ð§¹ûÅú×¢FCN-159ÖÎÁƳÉÈË»¼ÕßµÄORRΪ45.1%£¬£¬£¬£¬£¬Çå¾²ÐÔÓÅÒì¡£¡£¡£¡£¡£¡£¡£Í¬Ê±£¬£¬£¬£¬£¬FCN-159Õë¶Ô1ÐÍÉñ¾ÏËάÁö²¡Ïà¹ØµÄ´Ô×´Éñ¾ÏËάÁöµÄ³ÉÈË¢ñÆÚÁÙ´²Ñо¿Êý¾Ý¿ËÈÕҲͬ²½½ÒÏþÓÚ¹ú¼ÊÆÚ¿¯BMC Medicine£¨2023 IF=9.3£©[2]¡£¡£¡£¡£¡£¡£¡£Ñо¿Ð§¹ûÏÔʾ£¬£¬£¬£¬£¬FCN-159ÄÍÊÜÐÔÓÅÒ죬£¬£¬£¬£¬²»Á¼ÊÂÎñ¿É¿Ø£¬£¬£¬£¬£¬²¢ÔÚNF-1Ïà¹ØPN»¼ÕßÖÐÏÔʾ³öÓÐÏ£ÍûµÄ¿¹Ö×Áö»îÐÔ£¬£¬£¬£¬£¬ÖµµÃ½øÒ»²½Ñо¿¡£¡£¡£¡£¡£¡£¡£
£¨Í¼ÎªBMC MedicineÔÎĽÒÏþÐÅÏ¢£©
FCN-159ƬÊÇÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©×ÔÖ÷Ñз¢µÄÁ¢ÒìÐÍС·Ö×Ó»¯Ñ§Ò©Î£¬£¬£¬£¬ÄâÖ÷ÒªÓÃÓÚÍíÆÚʵÌåÁö¡¢IÐÍÉñ¾ÏËάÁö¡¢×é֯ϸ°ûÖ×Áö¡¢ÐÂÎÅÂö»ûÐεȵÄÖÎÁÆ¡£¡£¡£¡£¡£¡£¡£ËüÊÇÒ»¿îMEK1/2Ñ¡ÔñÐÔÒÖÖƼÁ£¬£¬£¬£¬£¬¿ÉÒÔÒÖÖÆRASͨ·Òì³£ÒýÆðµÄÖ×ÁöÔöÖ³¡£¡£¡£¡£¡£¡£¡£¸ÃÐÂÒ©ÓÃÓÚ³ÉÈË I ÐÍÉñ¾ÏËάÁöµÄÖÎÁÆÓÚÖйú¾³ÄÚ£¨²»°üÀ¨¸Û°Ą̈µØÇø£¬£¬£¬£¬£¬ÏÂͬ£©´¦ÓÚ III ÆÚÁÙ´²ÊÔÑé½×¶Î£¬£¬£¬£¬£¬¸ÃÐÂÒ©ÓÃÓÚ³ÉÈ˺Ͷùͯ I ÐÍÉñ¾ÏËάÁöÖÎÁƵÄÖйú¡¢ÃÀ¹ú¼°Å·Ö޵Ĺú¼Ê¶àÖÐÐÄ II ÆÚÁÙ´²ÊÔÑéÈÔÔÚ¾ÙÐÐÖУ»£»£»£»£»¸ÃÐÂÒ©ÓÃÓÚ×é֯ϸ°ûÖ×Áö¡¢³õ¼¶±ðÄÔ½ºÖÊÁöÒÔ¼°ÐÂÎÅÂö»ûÐεÄÖÎÁÆ»®·ÖÓÚÖйú¾³ÄÚ´¦ÓÚII ÆÚÁÙ´²ÊÔÑé½×¶Î£»£»£»£»£»¸ÃÐÂÒ©ÓÃÓÚÖÎÁƶùͯÀʸñººË¹Ï¸°û×é֯ϸ°ûÔöÉúÖ¢/Àʸñº±Ï¸°û×é֯ϸ°ûÔöÉúÖ¢µÄIIÆÚÁÙ´²ÊÔÑéÉêÇëÒÑ»ñ¹ú¼ÒÒ©¼à¾ÖÅú×¼¡£¡£¡£¡£¡£¡£¡£
²Î¿¼ÎÄÏ×
1.?Jett K, Friedman JM. Clinical and genetic aspects of neurofibromatosis 1. Genet Med 2010;?12:1-11..
2.?Hu X, et al. Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of?FCN-159?in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas. BMC Med. 2023 Jul 3;21(1):230. doi: 10.1186/s12916-023-02927-2.
¹ØÓÚÍ»ÆÆÐÔÁÆ·¨È϶¨
ΪÃãÀøÑо¿ºÍ´´Ôì¾ßÓÐÏÔ×ÅÁÙ´²ÓÅÊƵÄÒ©Î£¬£¬£¬£¬¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ£¨CDE£©Ðû²¼ÁË¡¶¹ú¼ÒÒ©¼à¾Ö¹ØÓÚÐû²¼£¼Í»ÆÆÐÔÖÎÁÆÒ©ÎïÉóÆÀÊÂÇé³ÌÐò£¨ÊÔÐУ©£¾µÈÈý¸öÎļþµÄͨ¸æ¡·£¨2020ÄêµÚ82ºÅ£©£¬£¬£¬£¬£¬Ã÷È·ÁËÍ»ÆÆÐÔÁÆ·¨µÄÄÉÈë¹æÄ££ºÒ©ÎïÁÙ´²ÊÔÑéʱ´ú£¬£¬£¬£¬£¬ÓÃÓÚ·ÀÖÎÑÏÖØΣ¼°ÉúÃü»òÕßÑÏÖØÓ°ÏìÉúÑÄÖÊÁ¿µÄ¼²²¡ÇÒÉÐÎÞÓÐÓ÷ÀÖÎÊֶλòÕßÓëÏÖÓÐÖÎÁÆÊÖ¶ÎÏà±ÈÓÐ×ã¹»Ö¤¾ÝÅú×¢¾ßÓÐÏÔ×ÅÁÙ´²ÓÅÊƵÄÁ¢ÒìÒ©»òÕ߸ÄÁ¼ÐÍÐÂÒ©µÈ¡£¡£¡£¡£¡£¡£¡£Ò©ÉóÖÐÐĶÔÄÉÈëÍ»ÆÆÐÔÖÎÁÆÒ©Îï³ÌÐòµÄÒ©ÎïÓÅÏÈÉèÖÃ×ÊÔ´¾ÙÐÐÏàͬ½»Á÷£¬£¬£¬£¬£¬ÔöÇ¿Ö¸µ¼²¢Ôö½øÒ©ÎïÑз¢¡£¡£¡£¡£¡£¡£¡£
¹ØÓÚÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©
ÉϺ£ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©£¨¼¯ÍÅ£©¹É·ÝÓÐÏÞ¹«Ë¾£¨¡°ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©¡±£¬£¬£¬£¬£¬¹ÉƱ´úÂ룺600196.SH£¬£¬£¬£¬£¬02196.HK£©½¨ÉèÓÚ1994 Ä꣬£¬£¬£¬£¬ÊÇÒ»¼ÒÖ²¸ùÖйú¡¢Á¢ÒìÇý¶¯µÄÈ«Çò»¯Ò½Ò©¿µ½¡¹¤Òµ¼¯ÍÅ£¬£¬£¬£¬£¬Ö±½ÓÔËÓªµÄÓªÒµ°üÀ¨ÖÆÒ©¡¢Ò½ÁÆÆ÷еÓëҽѧÕï¶Ï¡¢Ò½ÁÆ¿µ½¡Ð§ÀÍ£¬£¬£¬£¬£¬²¢Í¨¹ý²Î¹É¹úÒ©¿Ø¹ÉÁýÕÖµ½Ò½Ò©ÉÌÒµÁìÓò¡£¡£¡£¡£¡£¡£¡£
ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©ÒÔ»¼ÕßΪÖÐÐÄ¡¢ÁÙ´²ÐèÇóΪµ¼Ïò£¬£¬£¬£¬£¬Í¨¹ý×ÔÖ÷Ñз¢¡¢ÏàÖú¿ª·¢¡¢ÔÊÐíÒý½ø¡¢Éî¶È·õ»¯µÄ·½·¨£¬£¬£¬£¬£¬Ò»Á¬¸»ºñÁ¢Òì²úÆ·¹ÜÏߣ¬£¬£¬£¬£¬ÌáÉýFIC£¨First-in-class£¬£¬£¬£¬£¬¼´Í¬ÀàÊ×´´£©ÓëBIC£¨Best-in-class£¬£¬£¬£¬£¬¼´Í¬Àà×î¼Ñ£©ÐÂÒ©µÄÑо¿ÓëÁÙ´²¿ª·¢ÄÜÁ¦£¬£¬£¬£¬£¬¼ÓËÙÁ¢ÒìÊÖÒպͲúÆ·µÄÑз¢ºÍת»¯ÂäµØ¡£¡£¡£¡£¡£¡£¡£
ÔÚ¡°4IN¡±£¨Á¢Òì Innovation¡¢¹ú¼Ê»¯ Internationalization¡¢ÖÇÄÜ»¯ Intelligentization¡¢ÕûºÏ Integration£©µÄÕ½ÂÔÖ¸µ¼Ï£¬£¬£¬£¬£¬ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©³Ð¼Ì¡°Á¢ÒìתÐÍ¡¢ÕûºÏÔËÓª¡¢ÎȽ¡ÔöÌí¡±µÄÉú³¤Ä£Ê½ÒÔ¼°Îª¹É¶«´´Á¢¼ÛÖµµÄÐÅÐÄ£¬£¬£¬£¬£¬Ò»Ö±ÔöÇ¿×ÔÖ÷Ñз¢ÓëÍⲿÏàÖú£¬£¬£¬£¬£¬¸»ºñ²úÆ·¹ÜÏߣ¬£¬£¬£¬£¬Ç¿»¯È«Çò»¯½á¹¹£¬£¬£¬£¬£¬ÌáÉýÔËӪЧÂÊ£¬£¬£¬£¬£¬Í¬Ê±£¬£¬£¬£¬£¬Æð¾¢ÍƽøÒ½ÁÆ¿µ½¡¹¤ÒµÏßÉÏÏßϽṹ£¬£¬£¬£¬£¬ÖÂÁ¦ÓÚ³ÉΪȫÇòÒ½ÁÆ¿µ½¡Êг¡µÄÒ»Á÷ÆóÒµ¡£¡£¡£¡£¡£¡£¡£
Ïàʶ¹«Ë¾¸ü¶à×ÊѶ£¬£¬£¬£¬£¬¿ÉµÇ¼¹ÙÍø£ºwww.fosunpharma.com¡£¡£¡£¡£¡£¡£¡£
?